CliffBio
small molecule

TOFACITINIB CITRATE

TOFACITINIB CITRATE

Loss of exclusivity—loss of exclusivity
CompanySAPTALIS PHARMACEUTICALS LLC

Drug detail

Brand nameTOFACITINIB CITRATE
Active ingredientTOFACITINIB CITRATE
StrengthEQ 1MG BASE/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2026
Marketing statusRX

More from SAPTALIS PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TOFACITINIB CITRATE patent cliff — loss of exclusivity — | CliffBio